Abstract
Know the result of disease severity and clinical results in community-acquired pneumonia (CAP) are preconditions for treatment options and management for health care resources. Various scoring systems as CURB-65 and SMART-COP have been developed to facilitate these awareness. However, the scoring systems have strengths and weaknesses against each other. In this study, we aimed to investigate the relationship between these two scoring systems with procalcitonin level which is highly sensitive in the diagnosis of community-acquired pneumonia. This study included hospitalized patients with diagnosis CAP to internal medicine service that had been admitted to the emergency department of Okmeydanı Training and Research Hospital between 01.01.2015 - 12.31.2015. CURB-65 and SMART-COP scores were calculated with data of patients in the study. We collected measured procalcitonin levels. As described previously during the study, patients who had 2 and over values for CURB-65 and who had values 3 or more for SMART-COP were classified as high risk and groupings were structured according to these values. IBM SPSS Statistics 22 (IBM SPSS, Turkey) programs were used to evaluate the results obtained in this study for statistical analysis. The study was conducted on a total of 124 cases, including 62 men (50%) and 62 women (50%). Their ages ranged from 21 to 93, average age of 73.81 ± 12.70 years. 72 of the cases (58.1%) had a CURB-65 score of 2 or more and 49 of the cases (39.5%) had a SMART-COP score of 3 or above. The cases’ procalcitonin levels which had 2 or above scores for CURB-65 had higher statistical significance than the cases that had 2 or less scores for CURB-65 (P:0,004; p<0,05). The cases’ procalcitonin levels that had 3 or above scores for SMART-COP had higher statistical significance than the cases which had 2 or less scores for SMART-COP (p :0,001; p<0,05). High procalcitonin levels were associated with the patients who had high scores in both scoring systems, and had a relationship with the severity and course of the disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.